[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591098":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":26,"locations":37,"responsibleParty":94,"collaborators":96,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":21,"enrollmentInfo":108,"targetDuration":21,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":123,"whyStopped":21,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Kidney transplant recipients followed since the day of the transplantation","EXPERIMENTAL",[12],"Other: blood sampling",{"label":14,"type":10,"description":14,"interventionNames":15},"kidney transplant recipients with CMV viremia",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"blood sampling","Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.",[9,14],null,[23],{"name":24,"affiliation":5,"role":25},"Alexandra Serris","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Alexandra Serris, MD, PhD","CONTACT","0144 381799","+33","alexandra.serris@aphp.fr",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Hélène Morel","0171196346","helene.morel@aphp.fr",[38,55,69,86],{"facility":39,"status":21,"city":40,"state":21,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hôpital Bicêtre","Le Kremlin-Bicêtre","94270","France","FR",{"type":45,"coordinates":46},"Point",[47,48],2.36073,48.81471,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":53,"phoneExt":31,"email":54},"Renaud Snanoudj, MD, PhD","0145212721","renaud.snanoudj@aphp.fr",{"facility":56,"status":21,"city":57,"state":21,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Hôpital européen Georges Pompidou","Paris","75015",{"type":45,"coordinates":60},[61,62],2.3488,48.85341,{"lat":62,"lon":61},[65],{"name":66,"role":29,"phone":67,"phoneExt":31,"email":68},"Eric Thervet, M.D., PhD","0156095700","eric.thervet@aphp.fr",{"facility":70,"status":21,"city":57,"state":21,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Hôpital Necker-Enfants Malades",{"type":45,"coordinates":72},[61,62],{"lat":62,"lon":61},[75,77,79,82,84],{"name":28,"role":29,"phone":76,"phoneExt":21,"email":32},"+33144381799",{"name":78,"role":29,"phone":21,"phoneExt":21,"email":21},"Serris",{"name":80,"role":81,"phone":21,"phoneExt":21,"email":21},"Fanny Lanternier, M.D., PhD","SUB_INVESTIGATOR",{"name":83,"role":81,"phone":21,"phoneExt":21,"email":21},"Dany Anglicheau, M.D., PhD",{"name":85,"role":81,"phone":21,"phoneExt":21,"email":21},"Julien Zuber, M.D., PhD",{"facility":87,"status":21,"city":57,"state":21,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":88,"geoPoint":90,"contacts":91},"Insitut Pasteur",{"type":45,"coordinates":89},[61,62],{"lat":62,"lon":61},[92,93],{"name":28,"role":29,"phone":76,"phoneExt":21,"email":32},{"name":78,"role":29,"phone":21,"phoneExt":21,"email":21},{"type":95,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[97],{"name":98,"class":6},"URC-CIC Paris Descartes Necker Cochin","100591098","cmv-associated-immunomodulation-in-renal-transplant-patients-100591098",false,"NCT06976008","CMV-associated Immunomodulation in Renal Transplant Patients","IMMCMV","Inclusion Criteria:\n\n1. st cohort :\n\n   * Age \\> 18 years\n   * patients with end-stage renal failure programmed for kidney transplantation with a live donor\n2. nd cohort :\n\n   * Age \\> 18 years\n   * kidney transplant recipient with CMV viremia\n\nExclusion Criteria:\n\n\\- Patients under guardianship, curatorship, legal protection.\n\nFor patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor :\n\n* Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion\n* patients receiving a desensitization protocol (ABO or anti-HLA)","ALL","18 Years",{"count":109,"type":110},60,"ESTIMATED","INTERVENTIONAL",[113],"NA","Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.",[116],"Kidney Transplantation",[118,119,120,121,122],"Kidney transplant","Solid organ transplantation","Cytomegalovirus infection","Immunomodulatory effect of cytomegalovirus infection","Heterologous infection","NOT_YET_RECRUITING","2025-09-05",{"date":126,"type":127},"2025-09-12","ACTUAL",{"date":129,"type":110},"2025-10-01",{"date":131,"type":110},"2029-10-01",{"name":5,"class":6},4]